Glucagon-like peptide 2 oral - Cyclo Therapeutics
Alternative Names: Oral GLP-2 - Cyclo TherapeuticsLatest Information Update: 01 Jan 2024
At a glance
- Originator Applied Molecular Transport
- Developer Cyclo Therapeutics
- Class Glucagon-like peptides; Recombinant fusion proteins
- Mechanism of Action Glucagon-like peptide 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal disorders
Most Recent Events
- 27 Dec 2023 Applied Molecular Transport has merged with Cyclo Therapeutics to form Cyclo Therapeutics
- 22 Mar 2023 Discontinued - Preclinical for Gastrointestinal disorders in USA (PO) (Applied Molecular Transport pipeline, March 2023)
- 21 Sep 2022 Preclinical trials in Gastrointestinal disorders in USA (PO) prior to September 2022 (Applied Molecular Transport pipeline, September 2022)